News

On this episode of Stock Movers: - Novo Nordisk (NVO) shares are lower as it disappointed investors hoping for concrete turnaround plans from Chief Executive Officer Mike Doustdar after losing its lead in the obesity market to Eli Lilly & Co. The company pledged to launch more than five blockbusters and deliver more than $23 billion in new sales in coming years, but investors are selling shares due to lack of concrete news. - Arhaus (ARHS) is moving after Jefferies upgraded the furniture company to buy from hold, writing that it has "newfound optimism on the retailer's strategy to elevate brand awareness" and improve market share. - Accenture (ACN) is up on news Anthropic is partnering with Accenture to test the safety of its advanced artificial intelligence models by embedding evaluators from the consulting firm directly within its operations.

Novo Nordisk plans to launch at least five multi-blockbuster drugs by 2030 and is targeting pipeline drug sales of $23 billion by 2035.

Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was deliberately selling less medicine than people wanted to buy, and it kept saying so out loud.

Eli Lilly and Company (NYSE:LLY) has launched Foundayo in the United Kingdom, making Britain the first European country where the company’s oral treatment for weight management and type 2 diabetes is available. The pill, known chemically as orforglipron, became available through private prescription after the UK medicines regulator authorised it on August 10. Its launch […]

Germany becomes the first EU market for oral Wegovy, testing Novo's early lead as Eli Lilly expands.

The once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event of at least one weight-related health condition.

Eli Lilly and Co (NYSE:LLY) has launched its once-daily weight-management and diabetes pill Foundayo in UK pharmacies, offering patients an oral alternative to injectable GLP-1 treatments. Foundayo, also known as orforglipron, is available from Monday through private prescription after the...

With a five-year EPS forecast of 28.38%, Eli Lilly and Company (NYSE:LLY) is among the 12 Best Future Stocks to Buy Right Now. On May 21, Eli Lilly and Company (NYSE:LLY) reported pivotal Phase 3 data for retatrutide that demonstrated weight loss of up to 26.1% at 80 weeks and more than 30% at 104 weeks in […]

Novo will sell 1.5 mg, 4 mg and 9 mg Ozempic pills as it rebrands Rybelsus in the US.